scholarly journals Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary

2016 ◽  
Vol 12 (6) ◽  
pp. 588-590 ◽  
Author(s):  
Matthew I. Milowsky ◽  
R. Bryan Rumble ◽  
Cheryl T. Lee
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Oncology ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
European Association ◽  
Metastatic Bladder Cancer ◽  
American Society ◽  
Muscle Invasive ◽  
European Association Of Urology

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

2016 ◽  
Vol 34 (16) ◽  
pp. 1945-1952 ◽  
Author(s):  
Matthew I. Milowsky ◽  
R. Bryan Rumble ◽  
Christopher M. Booth ◽  
Timothy Gilligan ◽  
Libni J. Eapen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Radical Cystectomy ◽  
Clinical Oncology ◽  
Combination Chemotherapy ◽  
European Association ◽  
Metastatic Bladder Cancer ◽  
American Society ◽  
Muscle Invasive ◽  
European Association Of Urology

Purpose To endorse the European Association of Urology guideline on muscle-invasive (MIBC) and metastatic bladder cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The guideline on MIBC and metastatic bladder cancer was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and recommendations. Results The ASCO Endorsement Panel determined that the recommendations from the European Association of Urology guideline on MIBC and metastatic bladder cancer, published online in March 2015, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses the guideline on MIBC and metastatic bladder cancer and has added qualifying statements, including highlighting the use of chemoradiotherapy for select patients with MIBC and recommending a preference for clinical trials in the treatment of metastatic disease in the second-line setting. Recommendations Multidisciplinary care for patients with MIBC and metastatic bladder cancer is critical. The standard treatment of MIBC (cT2-T4a N0M0) is neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy. In cisplatin-ineligible patients, radical cystectomy alone is recommended. Adjuvant cisplatin-based chemotherapy may be offered to high-risk patients who have not received neoadjuvant therapy. Chemoradiotherapy may be offered as an alternative to cystectomy in appropriately selected patients with MIBC and in some patients for whom cystectomy is not an option. Metastatic disease should be treated with cisplatin-containing combination chemotherapy or with carboplatin combination chemotherapy or single agents in patients ineligible for cisplatin. Additional information is available at http://www.asco.org/endorsements/MIBC and www.asco.org/guidelineswiki .

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

2021 ◽  
Vol 79 (1) ◽  
pp. 82-104 ◽  
Author(s):  
J. Alfred Witjes ◽  
Harman Max Bruins ◽  
Richard Cathomas ◽  
Eva M. Compérat ◽  
Nigel C. Cowan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
European Association ◽  
Metastatic Bladder Cancer ◽  
Muscle Invasive ◽  
European Association Of Urology

scholarly journals Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline

2013 ◽  
Vol 4 (4) ◽  
pp. 263
Author(s):  
Brendan J.W. Miles ◽  
Adrian S. Fairey ◽  
Michael Eliasziw ◽  
Eric P. Estey ◽  
Peter Venner ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Oncology Group ◽  
Chimiothérapie Néoadjuvante ◽  
Cancer De La Vessie ◽  
Before And After ◽  
Muscle Invasive

Introduction: The objective of this study was to compare referraland treatment rates of neoadjuvant chemotherapy for patients withmuscle-invasive bladder cancer before and after publication of aclinical practice guideline.Methods: This was a retrospective comparative cohort study of236 patients diagnosed with clinical stage ≥ T2 bladder cancerin Alberta, Canada. Patients were divided into 2 groups basedon the time of diagnosis relative to the publication of the AlbertaGenitourinary Oncology Group Clinical Practice Guideline onBladder Cancer (CPG), which recommends cisplatin-based neoadjuvantchemotherapy for muscle-invasive disease. The pre-CPGgroup included patients (n = 129) diagnosed prior to publicationof the CPG (November 1, 2002 to October 31, 2004, inclusively).The post-CPG group included patients (n = 107) diagnosed afterpublication of the CPG (November 1, 2005 to October 31, 2007).There was an accrual blackout period of 6 months before and afterthe CPG release date. The primary analysis compared the twogroups with respect to neoadjuvant chemotherapy referral rates,treatment-offered rates and treatment-administered rates.Results: Referral to medical oncology regarding neoadjuvantchemotherapy occurred in 2.3% and 23.4% of patients in thepre- and post-CPG groups, respectively (p < 0.01). Neoadjuvantchemotherapy was offered to 0.8% and 18.7% of patients in thepre- and post-CPG groups, respectively (p < 0.01). Neoadjuvantchemotherapy was administered to 0.8% and 14.0% of patients inthe pre- and post-CPG groups, respectively (p < 0.01).Interpretation: Neoadjuvant referral and treatment rates increasedafter publication of the CPG. However, overall referral and treatmentrates remained low, which warrants additional exploration.Introduction : L’objectif de l’étude était de comparer les taux derecommandation et de traitement par chimiothérapie néoadjuvantechez les patients atteints de cancer de la vessie avec envahissementmusculaire avant et après la publication d’un guide de pratiqueclinique.Méthodologie : Il s’agit ici d’une étude comparative rétrospectivede cohorte comptant 236 patients de l’Alberta, au Canada, chezqui on avait diagnostiqué un cancer de la vessie de stade cliniqueT2 ou pire. Les patients ont été répartis en 2 groupes selon que leurdiagnostic avait été posé avant ou après la publication du guidede pratique clinique sur le cancer de la vessie (GPC) de l’AlbertaGenitourinary Oncology Group, qui recommande une chimiothérapienéoadjuvante à base de cisplatine pour le traitement descas de cancer avec envahissement musculaire. Le groupe pré-GPCcomprenait des patients (n = 129) chez qui le diagnostic avaitété posé avant la publication du GPC (du 1er novembre 2002 au31 octobre 2004, inclusivement). Le groupe post-GPC incluait despatients (n = 107) chez qui le diagnostic avait été posé après lapublication du GPC (du 1er novembre 2005 au 31 octobre 2007).Une période cumulative de censure a été calculée 6 mois avant etaprès la date de publication du GPC. L’analyse préliminaire a comparéles deux groupes quant aux taux de recommandation de lachimiothérapie néoadjuvante, aux taux d’offre et d’administrationdu traitement.Résultats : La chimiothérapie néoadjuvante a été recommandée chez2,3 et 23,4 % des patients dans les groupes pré-GPC et post-GPC,respectivement (p < 0,01). Elle a été offerte à 0,8 % et 18,7 % despatients de ces mêmes groupes (p < 0,01), et administrée à 0,8 et14,0 % des patients des groupes pré-GPC et post-GPC, respectivement(p < 0,01).Interprétation : Les taux de recommandation et de traitement concernantla chimiothérapie néoadjuvante ont augmenté après lapublication du GPC, mais sont tout de même demeurés faibles,ce qui nécessite une analyse plus poussée.

Sign in / Sign up

Export Citation Format

Share Document